$KVAC
Keen Vision Acquisition Corp

2023 Q3 Form 10-Q Financial Statement

#000121390023073218 Filed on September 01, 2023

View on sec.gov

Income Statement

Concept 2023 Q3 2023 Q2 2023 Q1
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin
YoY Change
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $305.7K $0.00
YoY Change
Operating Profit
YoY Change
Interest Expense $20.00 $0.00
YoY Change
% of Operating Profit
Other Income/Expense, Net $19.00 $1.00
YoY Change 850.0%
Pretax Income -$305.7K $0.00
YoY Change
Income Tax
% Of Pretax Income
Net Earnings -$305.7K -$845.00 -$4.032K
YoY Change 140124.31% -84600.0% 2190.91%
Net Earnings / Revenue
Basic Earnings Per Share $0.00
Diluted Earnings Per Share -$0.02 $0.00
COMMON SHARES
Basic Shares Outstanding 19.37M shares 3.250M shares
Diluted Shares Outstanding 3.250M shares

Balance Sheet

Concept 2023 Q3 2023 Q2 2023 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $735.4K $0.00
YoY Change
Cash & Equivalents $735.4K $4.664K $1.486K
Short-Term Investments
Other Short-Term Assets $314.3K $0.00
YoY Change
Inventory
Prepaid Expenses $314.3K $425.00
Receivables
Other Receivables
Total Short-Term Assets $1.050M $5.089K
YoY Change
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $152.8M
YoY Change
Other Assets $0.00 $290.0K
YoY Change
Total Long-Term Assets $152.8M $290.1K
YoY Change
TOTAL ASSETS
Total Short-Term Assets $1.050M $5.089K
Total Long-Term Assets $152.8M $290.1K
Total Assets $153.8M $295.2K
YoY Change
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable
YoY Change
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $280.0K
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $30.00K $280.0K
YoY Change
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $2.990M
YoY Change
Total Long-Term Liabilities $2.990M $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $30.00K $280.0K
Total Long-Term Liabilities $2.990M $0.00
Total Liabilities $3.020M $278.9K
YoY Change
SHAREHOLDERS EQUITY
Retained Earnings -$3.367M -$8.643K
YoY Change
Common Stock $442.00 $374.00
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$1.970M $16.36K $17.20K
YoY Change
Total Liabilities & Shareholders Equity $153.8M $295.2K
YoY Change

Cashflow Statement

Concept 2023 Q3 2023 Q2 2023 Q1
OPERATING ACTIVITIES
Net Income -$305.7K -$845.00 -$4.032K
YoY Change 140124.31% -84600.0% 2190.91%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$619.5K $0.00 -$2.072K
YoY Change
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities -$151.4M
YoY Change
Cash From Investing Activities -$151.4M
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 152.7M -70.00K -$74.15K
YoY Change
NET CHANGE
Cash From Operating Activities -619.5K 0.000 -$2.072K
Cash From Investing Activities -151.4M
Cash From Financing Activities 152.7M -70.00K -$74.15K
Net Change In Cash 152.1M -70.00K -$76.22K
YoY Change
FREE CASH FLOW
Cash From Operating Activities -$619.5K $0.00 -$2.072K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-06-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-41753
dei Entity Registrant Name
EntityRegistrantName
KEEN VISION ACQUISITION CORPORATION
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
D8
dei Entity Address Address Line1
EntityAddressAddressLine1
37 Greenbriar Drive
dei Entity Address City Or Town
EntityAddressCityOrTown
Summit
dei Entity Address State Or Province
EntityAddressStateOrProvince
NJ
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
07901
dei City Area Code
CityAreaCode
(203)
dei Local Phone Number
LocalPhoneNumber
609-1394
dei Entity Current Reporting Status
EntityCurrentReportingStatus
No
dei Entity Shell Company
EntityShellCompany
true
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
19366075 shares
CY2023Q2 us-gaap Cash
Cash
4664 usd
CY2022Q4 us-gaap Cash
Cash
77709 usd
CY2023Q2 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
425 usd
CY2022Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
2598 usd
CY2023Q2 us-gaap Assets Current
AssetsCurrent
5089 usd
CY2022Q4 us-gaap Assets Current
AssetsCurrent
80307 usd
CY2023Q2 us-gaap Deferred Costs
DeferredCosts
290140 usd
CY2022Q4 us-gaap Deferred Costs
DeferredCosts
114500 usd
CY2023Q2 us-gaap Assets
Assets
295229 usd
CY2022Q4 us-gaap Assets
Assets
194807 usd
CY2023Q2 us-gaap Notes Payable Current
NotesPayableCurrent
278872 usd
CY2022Q4 us-gaap Notes Payable Current
NotesPayableCurrent
173573 usd
CY2023Q2 us-gaap Liabilities
Liabilities
278872 usd
CY2022Q4 us-gaap Liabilities
Liabilities
173573 usd
CY2023Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000 shares
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000 shares
CY2023Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
3737500 shares
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
3737500 shares
CY2023Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
3737500 shares
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
3737500 shares
CY2023Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
24626 usd
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
24626 usd
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-8643 usd
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-3766 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
16357 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
21234 usd
CY2023Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
295229 usd
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
194807 usd
CY2023Q2 us-gaap Direct Operating Costs
DirectOperatingCosts
845 usd
us-gaap Direct Operating Costs
DirectOperatingCosts
4878 usd
us-gaap Direct Operating Costs
DirectOperatingCosts
177 usd
CY2022Q2 us-gaap Interest And Other Income
InterestAndOtherIncome
1 usd
us-gaap Interest And Other Income
InterestAndOtherIncome
1 usd
us-gaap Interest And Other Income
InterestAndOtherIncome
2 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-845 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
1 usd
us-gaap Net Income Loss
NetIncomeLoss
-4877 usd
us-gaap Net Income Loss
NetIncomeLoss
-175 usd
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
3250000 shares
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
3250000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
3250000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
3250000 shares
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
21234 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-4032 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
17202 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-845 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
16357 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
21927 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-176 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
21751 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
1 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
21752 usd
us-gaap Net Income Loss
NetIncomeLoss
-4877 usd
us-gaap Net Income Loss
NetIncomeLoss
-175 usd
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-2173 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-2704 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-175 usd
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
175640 usd
us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
105299 usd
us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
47500 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-70341 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
47500 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-73045 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
47325 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
77709 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
24924 usd
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
4664 usd
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
72249 usd
kvac Public Warrant Description
PublicWarrantDescription
Each Public Unit consists of one ordinary share and one redeemable warrant (“Public Warrant”) to purchase one ordinary share at an exercise price of $11.50 per share.
kvac Private Warrant Description
PrivateWarrantDescription
Each Private Placement Unit consists of one ordinary share and one redeemable warrant (“Private Warrant”) to purchase one ordinary share at an exercise price of $11.50 per whole share.
us-gaap Sale Leaseback Transaction Transaction Costs Financing Activities
SaleLeasebackTransactionTransactionCostsFinancingActivities
6597980 usd
us-gaap Investment Banking Advisory Brokerage And Underwriting Fees And Commissions
InvestmentBankingAdvisoryBrokerageAndUnderwritingFeesAndCommissions
2990000 usd
CY2023Q2 us-gaap Deferred Costs Current
DeferredCostsCurrent
2990000 usd
CY2023Q2 us-gaap Other Ownership Interests Offering Costs
OtherOwnershipInterestsOfferingCosts
617980 usd
CY2023Q3 us-gaap Temporary Equity Aggregate Amount Of Redemption Requirement
TemporaryEquityAggregateAmountOfRedemptionRequirement
151368750 usd
kvac Public Price Unit
PublicPriceUnit
10.125
CY2023Q2 us-gaap Fair Value Investments Entities That Calculate Net Asset Value Per Share Percent Debt Securities
FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerSharePercentDebtSecurities
0.80 pure
CY2023Q2 us-gaap Other Intangible Assets Net
OtherIntangibleAssetsNet
5000001 usd
us-gaap Debt Instrument Redemption Price Percentage
DebtInstrumentRedemptionPricePercentage
0.15 pure
kvac Public Price Per Share
PublicPricePerShare
10.125
CY2023Q2 us-gaap Assets Held In Trust Current
AssetsHeldInTrustCurrent
1495000 usd
CY2023Q2 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
0.1
kvac Outstanding Public Shares
OutstandingPublicShares
1 pure
us-gaap Other Expenses
OtherExpenses
50000 usd
kvac Working Capital Deficit
WorkingCapitalDeficit
273783 usd
us-gaap Net Income Loss
NetIncomeLoss
-4877 usd
us-gaap Use Of Estimates
UseOfEstimates
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0in"></td><td style="width: 0.25in; text-align: left">●</td><td style="text-align: justify">Use of estimates</td> </tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of unaudited condensed financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statement.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statement, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ significantly from those estimates.</p>
us-gaap Stock Issued During Period Shares Share Based Compensation Forfeited
StockIssuedDuringPeriodSharesShareBasedCompensationForfeited
487500 shares
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0in"></td><td style="width: 0.25in; text-align: left">●</td><td style="text-align: justify">Concentration of credit risk</td> </tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Financial instruments that potentially subject the Company to concentration of credit risk consist of a cash account in a financial institution. The Company has not experienced losses on this account and management believes the Company is not exposed to significant risks on such account.</p>
us-gaap Sale Of Stock Number Of Shares Issued In Transaction
SaleOfStockNumberOfSharesIssuedInTransaction
14950000 shares
CY2021Q3 us-gaap Stock Issued During Period Shares Issued For Services
StockIssuedDuringPeriodSharesIssuedForServices
3737500 shares
CY2021Q3 us-gaap Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation
WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
487500 shares
CY2021Q3 srt Financing Receivable Allowance For Credit Loss To Outstanding Percent
FinancingReceivableAllowanceForCreditLossToOutstandingPercent
0.20 pure
CY2021Q3 kvac Aggregate Purchase Price Amount
AggregatePurchasePriceAmount
25000 usd
us-gaap Sponsor Fees
SponsorFees
278872 usd
CY2022 us-gaap Sponsor Fees
SponsorFees
173573 usd
us-gaap Affiliate Costs
AffiliateCosts
10000 usd
CY2023Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000 shares
CY2023Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
us-gaap Common Stock Voting Rights
CommonStockVotingRights
one
CY2023Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
3737500 shares
CY2023Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
3737500 shares
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
3737500 shares
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
3737500 shares
kvac Percentage Of Issued And Outstanding Shares
PercentageOfIssuedAndOutstandingShares
0.20 pure
CY2023Q2 us-gaap Warrants And Rights Outstanding Term
WarrantsAndRightsOutstandingTerm
P5Y
us-gaap Class Of Warrant Or Right Expense Or Revenue Recognized
ClassOfWarrantOrRightExpenseOrRevenueRecognized
The Company may call the warrants for redemption, in whole and not in part, at a price of $0.01 per warrant: ●upon not less than 30 days’ prior written notice of redemption to each warrant holder, ●if, and only if, the reported last sale price of the ordinary share equals or exceeds $16.50 per share, for any 20 trading days within a 30 trading days period ending on the third trading day prior to the notice of redemption to Public Warrant holders
kvac Effective Issue Price Per Share
EffectiveIssuePricePerShare
9.35
kvac Percentage Of Aggregate Gross Proceeds
PercentageOfAggregateGrossProceeds
0.60 pure
CY2023Q2 us-gaap Investment Company Market Value Per Share
InvestmentCompanyMarketValuePerShare
9.35
CY2023Q2 kvac Percentage Of Exercise Price Warrants
PercentageOfExercisePriceWarrants
1.15 pure
CY2023Q2 us-gaap Temporary Equity Redemption Price Per Share
TemporaryEquityRedemptionPricePerShare
16.5
kvac Percentage Of Market Value
PercentageOfMarketValue
1.65 pure
us-gaap Underwriting Expense Ratio
UnderwritingExpenseRatio
0.02 pure
us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
2990000 usd
CY2023Q2 us-gaap Sale Of Stock Number Of Shares Issued In Transaction
SaleOfStockNumberOfSharesIssuedInTransaction
14950000 shares
CY2023Q2 kvac Additional Units
AdditionalUnits
1950000 usd
CY2023Q2 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
10
CY2023Q2 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
149500000 usd
CY2023Q2 kvac Sponsor Units Issued
SponsorUnitsIssued
678575 shares
CY2023Q2 us-gaap Sale Of Stock Price Per Share
SaleOfStockPricePerShare
10
CY2023Q2 us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
6785750 usd
CY2022Q2 us-gaap Direct Operating Costs
DirectOperatingCosts
usd
CY2023Q2 us-gaap Interest And Other Income
InterestAndOtherIncome
usd
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
3250000 shares
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
3250000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
3250000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
3250000 shares
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.00
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.00
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.00
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.00
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
usd
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Entity Central Index Key
EntityCentralIndexKey
0001889983

Files In Submission

Name View Source Status
0001213900-23-073218-index-headers.html Edgar Link pending
0001213900-23-073218-index.html Edgar Link pending
0001213900-23-073218.txt Edgar Link pending
0001213900-23-073218-xbrl.zip Edgar Link pending
f10q0623ex31-1_keenvision.htm Edgar Link pending
f10q0623ex31-2_keenvision.htm Edgar Link pending
f10q0623ex32-1_keenvision.htm Edgar Link pending
f10q0623ex32-2_keenvision.htm Edgar Link pending
f10q0623_keenvision.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
kvac-20230630.xsd Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
kvac-20230630_cal.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
kvac-20230630_def.xml Edgar Link unprocessable
kvac-20230630_lab.xml Edgar Link unprocessable
kvac-20230630_pre.xml Edgar Link unprocessable
f10q0623_keenvision_htm.xml Edgar Link completed
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending